The human studies
retatrutide research, from the first trial to open questions
See what changed in people, how long each trial ran, and what researchers still haven't tested.
What did the first trials measure?
Human trials tracked blood sugar, body weight, liver fat, and unwanted effects. Retatrutide was the lab-made drug in those trials. It is a 39-amino-acid chain, meaning a chain made from small linked pieces. This detail tells how the drug is built, not what it will do for you. The first work included a small early Phase 1b trial and larger Phase 2 tests of benefit and common harm [1][2][4][5].
People received a known study drug and returned for regular checks. Doctors could link each change to a set time and trial group. The weight, sugar, and liver findings deserve attention, but they don't amount to approval. Upset stomachs and a faster resting pulse appeared; long-term heart, kidney, and stopping effects remain unknown [1][9][15].
Why did the small Phase 1b trial lead to weekly shots?
The first human study included 72 adults with type 2 diabetes. They received a weekly shot and were followed for 12 weeks. Retatrutide had a half-life of about six days. That means the measured amount in blood took about six days to fall by half [4].
At the highest study steps, people lost 8.96 kilograms more than the placebo group over 12 weeks, on average [4]. The study's 90% range ran from 6.75 to 11.16 kilograms more, showing how far the group average might move through chance in a similar group. New side effects affected 63% of people and were mostly stomach problems [4]. This short trial couldn't settle lasting benefit or harm.
The first study found enough drug in blood for weekly tests to make sense. That finding explains why later trials kept the same timing. Those trials could include more people and run longer. Much larger groups would still be needed to find rare harm.
What fell in the mid-stage Phase 2 trials?
The 48-week weight trial included 338 adults with obesity or a related health problem. The 12 mg group lost 24.2% of starting weight on average. The no-drug group lost 2.1% [1]. Upset stomachs and resting pulse both rose with the study amount. Pulse was highest near week 24 [1].
The type 2 diabetes trial included 281 adults. Its main average-sugar result came at the 24-week check. The 12 mg group had a 2.02-percentage-point fall on that test. Weight fell 16.94% at 36 weeks; placebo changes were 0.01 points and 3.00% [2]. The summary reported no very low blood sugar or deaths [2].
The liver study included 98 people who started with at least 10% liver fat on an MRI-PDFF scan, a special scan for liver fat. At week 24, liver fat fell 42.9% in the 1 mg group and 82.4% in the 12 mg group. It rose 0.3% with placebo [5]. In the highest group, 86% got below 5%. The average drop was still 86.0% at week 48 [5].
The scan measures fat, but it can't show every kind of liver harm. A biopsy checks a small piece of liver and would answer other questions [8]. These Phase 2 trials were mid-stage tests with different people and health checks. No single trial gives the full account of benefit and harm.
What did the lab find about the three hormone messages?
A very strong microscope took pictures of frozen pieces too small to see in a usual lab. The pictures showed retatrutide fitting into three receiving parts on cells [3]. In cells in a dish, the GIP gut-hormone message was 8.9 times as strong as natural GIP. The GLP-1 and fuel-release messages were 0.3 and 0.4 as strong as their natural hormones [3].
Those numbers tell how the test cells reacted. They don't mean that benefit or harm will grow by the same amount in a person. The three messages may affect insulin, hunger, fuel use, and liver fat. Reviews say the fuel-releasing hormone may help the liver move and burn fat [7][14]. Human trials must show whether that idea helps people.
How do retatrutide vs tirzepatide differ?
GIP and GLP-1 are two gut-hormone messages copied by both drugs. Retatrutide also copies a third message that frees stored fuel. Tirzepatide uses GIP and GLP-1 but not that third message. This difference doesn't mean either drug is better for every person or health problem.
A Phase 3 plan, a large late trial, will compare the drugs. No finished head-to-head result appears here. The separate trials differed in who joined, how long they ran, and how missed visits were counted, while a 2024 review placed retatrutide among the strongest drugs of this kind studied for weight loss [11]. Later reviews also found large liver changes in fatty liver disease [8].
Reviews can explain the interest without naming a winner. Researchers must put both drugs in one trial and assign people by chance. Until that trial ends, calling either drug better runs ahead of the facts.
What do we still need to learn about the liver?
A 2026 review found hints of better liver health, but thin proof about liver scars [12]. A larger review combined trials of several drugs. Some blood tests improved, scans showed less liver fat, and estimates of scarring improved [13]. Yet another liver drug did better on some checks of scars and swelling. These weren't new trial results for retatrutide alone.
Another 2026 review described ways the drug might affect liver fat, swelling, and scars [14]. Eating less may be one reason. A change in how the liver moves and burns fat may be another. Those ideas don't prove that retatrutide can reverse liver scars.
The work began with close lab views of where the drug fits. Short studies then checked how long it stayed in blood and what people could bear. Phase 2 trials measured weight, sugar, and liver fat. Those Phase 2 findings can't show whether the changes prevent serious illness.
A future liver study needs a biopsy, which checks a small piece of liver for scars. Other studies must test lasting benefit, heart trouble, and change after stopping. A Phase 3 paper says a large late trial is now checking kidney health [9]. Retatrutide has strong early findings, but those later answers aren't in yet.